Louis M Staudt

List of Publications by Year in Descending Order

335 papers	62,598 citations	111 h-index	250 g-index
348 ext. papers	70,687 ext. citations	13.8 avg, IF	7.17 L-index

#	Paper	IF	Citations
335	In vivo CRISPR screens reveal a HIF-1□-mTOR-network regulates T follicular helper versus Th1 cells.. *Nature Communications*, **2022**, 13, 805	17.4	2
334	Structure of S1PR2-heterotrimeric G signaling complex.. *Science Advances*, **2022**, 8, eabn0067	14.3	0
333	Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. *Cancer Cell*, **2021**,	24.3	14
332	Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory and Untreated Mantle Cell Lymphoma: Safety, Efficacy, and Molecular Analysis. *Blood*, **2021**, 138, 3537-3537	2.2	0
331	Phase 2 Study of Acalabrutinib Window Prior to Frontline Therapy in Untreated Aggressive B-Cell Lymphoma: Preliminary Results and Correlatives of Response to Acalabrutinib. *Blood*, **2021**, 138, 524-524	2.2	0
330	Chromatin Accessibility Profiling to Increase Diagnostic Accuracy and Refine Cell-of-Origin Classification of Mature T-Cell Lymphomas. *Blood*, **2021**, 138, 809-809	2.2	
329	Novel Genetic Subgroups Inform on Shared Pathobiology within Adult and Pediatric Burkitt Lymphoma. *Blood*, **2021**, 138, 806-806	2.2	
328	Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma. *Blood Advances*, **2021**, 5, 5239-5257	7.8	1
327	Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma. *Leukemia and Lymphoma*, **2021**, 62, 2094-2106	1.9	1
326	The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment. *Cell*, **2021**, 184, 1661-1670	56.2	25
325	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. *Haematologica*, **2021**, 106, 2682-2693	6.6	12
324	Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP□□brutinib. *British Journal of Haematology*, **2021**, 194, 83-91	4.5	2
323	A Cyclin D1-Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma. *Clinical Cancer Research*, **2021**, 27, 213-225	12.9	2
322	Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. *Immunity*, **2021**, 54, 116-131.e10	32.3	18
321	Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. *Cancer Cell*, **2021**, 39, 38-53.e7	24.3	18
320	Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture. *Nature*, **2021**, 589, 299-305	50.4	56
319	The NCI Genomic Data Commons. *Nature Genetics*, **2021**, 53, 257-262	36.3	11

318	Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior. *Blood*, **2021**, 138, 1570-1582	2.2	1
317	Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing. *Nature Biotechnology*, **2021**, 39, 1141-1150	44.5	11
316	Overcoming Acquired Epigenetic Resistance to BTK Inhibitors. *Blood Cancer Discovery*, **2021**, 2, 630-647	7	3
315	Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. *Science Immunology*, **2020**, 5,	28	217
314	Regulation of B cell receptor-dependent NF-B signaling by the tumor suppressor KLHL14. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 6092-6102	11.5	9
313	CRISPR-based technology to silence the expression of lncRNAs. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 8225-8227	11.5	4
312	TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. *Cell*, **2020**, 182, 297-316.e27	56.2	23
311	TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. *Nature Medicine*, **2020**, 26, 577-588	50.5	22
310	A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. *Cancer Cell*, **2020**, 37, 551-568.e14	24.3	194
309	Rewiring of B cell receptor signaling by Epstein-Barr virus LMP2A. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 26318-26327	11.5	8
308	Gene Expression Profiling of Mediastinal Gray Zone Lymphoma and Its Relationship to Primary Mediastinal B-cell Lymphoma and Classical Hodgkin Lymphoma. *Blood Cancer Discovery*, **2020**, 1, 155-167	7	7
307	A novel model of controlling PD-L1 expression in ALK anaplastic large cell lymphoma revealed by CRISPR screening. *Blood*, **2019**, 134, 171-185	2.2	29
306	Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. *Journal of Clinical Oncology*, **2019**, 37, 1790-1799	2.2	156
305	Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. *Journal of Clinical Oncology*, **2019**, 37, 1285-1295	2.2	188
304	Reply to M. Skelin et al. *Journal of Clinical Oncology*, **2019**, 37, 2584-2585	2.2	
303	Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment. *Immunological Reviews*, **2019**, 291, 190-213	11.3	40
302	Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial. *Blood*, **2019**, 134, 354-354	2.2	6
301	PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma. *Blood*, **2019**, 134, 2869-2869	2.2	2

300	KLHL14 Is a Tumor Suppressor in Diffuse Large B-Cell Lymphoma. *Blood*, **2019**, 134, 2766-2766	2.2	
299	Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma. *Blood*, **2019**, 134, 3781-3781	2.2	
298	Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS. *Blood*, **2019**, 134, 2875-2875	2.2	
297	Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. *Blood*, **2019**, 133, 1664-1676	2.2	87
296	Defining, Identifying, and Understanding "Exceptional Responders" in Oncology Using the Tools of Precision Medicine. *Cancer Journal (Sudbury, Mass)*, **2019**, 25, 296-299	2.2	2
295	Secondary Metabolites from the Fungus Dictyosporium sp. and Their MALT1 Inhibitory Activities. *Journal of Natural Products*, **2019**, 82, 154-162	4.9	10
294	Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. *Blood*, **2019**, 133, 1313-1324	2.2	75
293	Taming the Heterogeneity of Aggressive Lymphomas for Precision Therapy. *Annual Review of Cancer Biology*, **2019**, 3, 429-455	13.3	12
292	TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib. *Cancer Research*, **2019**, 79, 360-371	10.1	23
291	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. *New England Journal of Medicine*, **2018**, 378, 1396-1407	59.2	780
290	Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma. *Cancer Cell*, **2018**, 34, 286-297.e10	24.3	44
289	A multiprotein supercomplex controlling oncogenic signalling in lymphoma. *Nature*, **2018**, 560, 387-391	50.4	172
288	Dose-Adjusted Teddi-R Induces Durable Complete Remissions in Relapsed and Refractory Primary CNS Lymphoma. *Blood*, **2018**, 132, 4195-4195	2.2	3
287	A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL). *Blood*, **2018**, 132, 784-784	2.2	13
286	Lkb1 deletion in murine B lymphocytes promotes cell death and cancer. *Experimental Hematology*, **2017**, 51, 63-70.e1	3.1	4
285	The NCI Genomic Data Commons as an engine for precision medicine. *Blood*, **2017**, 130, 453-459	2.2	147
284	Sharing Clinical and Genomic Data on Cancer - The Need for Global Solutions. *New England Journal of Medicine*, **2017**, 376, 2006-2009	59.2	25
283	Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. *Cancer Cell*, **2017**, 31, 833-843.e5	24.3	279

282	A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *Clinical Cancer Research*, **2017**, 23, 4127-4137	12.9	98
281	Isoform-Specific Expression and Feedback Regulation of E Protein TCF4 Control Dendritic Cell Lineage Specification. *Immunity*, **2017**, 46, 65-77	32.3	52
280	HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling. *Blood*, **2017**, 129, 598-608	2.2	16
279	New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. *Journal of Clinical Oncology*, **2017**, 35, 1668-1677	2.2	67
278	Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets. *Blood*, **2017**, 130, 1819-1831	2.2	42
277	Developing Cancer Informatics Applications and Tools Using the NCI Genomic Data Commons API. *Cancer Research*, **2017**, 77, e15-e18	10.1	17
276	Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay. *Haematologica*, **2017**, 102, e404-e406	6.6	13
275	PI3K□nhibition causes feedback activation of PI3K□ in the ABC subtype of diffuse large B-cell lymphoma. *Oncotarget*, **2017**, 8, 81794-81802	3.3	21
274	Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. *Leukemia and Lymphoma*, **2016**, 57, 717-20	1.9	11
273	Toward a Shared Vision for Cancer Genomic Data. *New England Journal of Medicine*, **2016**, 375, 1109-12	59.2	707
272	A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm. *Cancer Cell*, **2016**, 30, 764-778	24.3	84
271	Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E7260-E7267	11.5	37
270	Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E577-86	11.5	24
269	Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E2039-46	11.5	38
268	Burkitt Lymphoma Genome Sequencing Project (BLGSP): Introduction. *Blood*, **2016**, 128, 1760-1760	2.2	1
267	Molecular Subgroups of Peripheral T-Cell Lymphoma Evolve By Distinct Genetic Pathways. *Blood*, **2016**, 128, 4096-4096	2.2	1
266	Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303. *Blood*, **2016**, 128, 469-469	2.2	73
265	Genome-Scale ORF Screen for Mediators of NF-□ Activation in DLBCL. *Blood*, **2016**, 128, 4102-4102	2.2	

264	Comprehensive Genomic Analysis of Adult Burkitt Lymphoma Identifies the B-Cell Receptor Signaling Pathway As a Potential Therapeutic Target. *Blood*, **2016**, 128, 4095-4095	2.2	
263	Integrating Genomic Alterations in Diffuse Large B-Cell Lymphoma Identifies New Relevant Pathways and Potential Therapeutic Targets. *Blood*, **2016**, 128, 152-152	2.2	
262	B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice. *Blood*, **2016**, 127, 2732-41	2.2	78
261	General Biomarker Recommendations for Lymphoma. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	2
260	Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma. *Cancer Cell*, **2016**, 29, 494-507	24.3	72
259	Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma. *Blood*, **2016**, 127, 3127-32	2.2	45
258	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. *Journal of Clinical Oncology*, **2015**, 33, 2848-56	2.2	236
257	Protein Tyrosine Phosphatase PTPRS Is an Inhibitory Receptor on Human and Murine Plasmacytoid Dendritic Cells. *Immunity*, **2015**, 43, 277-88	32.3	27
256	Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. *Nature Medicine*, **2015**, 21, 922-6	50.5	707
255	Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. *Lancet Oncology, The*, **2015**, 16, 541-9	21.7	251
254	Bill Paul: The heart of immunology. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 14117-8	11.5	
253	Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 13447-54	11.5	105
252	Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. *Journal of Experimental Medicine*, **2015**, 212, 2189-201	16.6	112
251	Protein ubiquitination in lymphoid malignancies. *Immunological Reviews*, **2015**, 263, 240-56	11.3	18
250	Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. *Blood*, **2015**, 125, 1137-45	2.2	87
249	A roadmap for discovery and translation in lymphoma. *Blood*, **2015**, 125, 2175-7	2.2	16
248	ATM deficiency promotes development of murine B-cell lymphomas that resemble diffuse large B-cell lymphoma in humans. *Blood*, **2015**, 126, 2291-301	2.2	11
247	Primary diffuse large B-cell lymphoma associated with clonally-related monoclonal B lymphocytosis indicates a common precursor cell. *Haematologica*, **2015**, 100, e415-8	6.6	3

246	Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling. *American Journal of Surgical Pathology*, **2015**, 39, 1322-30	6.7	45
245	B-cell receptor signaling in diffuse large B-cell lymphoma. *Seminars in Hematology*, **2015**, 52, 77-85	4	139
244	Multicenter Phase 1b Dose-Escalation Study of Ibrutinib and Lenalidomide Combined with Dose-Adjusted EPOCH-R in Patients with Relapsed/Refractory DLBCL. *Blood*, **2015**, 126, 1527-1527	2.2	3
243	Phase I Study of Dose-Adjusted-Teddi-R with Ibrutinib in Untreated and Relapsed/Refractory Primary CNS Lymphoma. *Blood*, **2015**, 126, 472-472	2.2	21
242	Microrna-17~92 Cluster Upregulates NF-KB Activity Via Suppressing Multiple NF-KB Negative Regulators Mediating Ubiquitination. *Blood*, **2015**, 126, 3638-3638	2.2	
241	Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms. *Cancer Discovery*, **2014**, 4, 480-93	24.4	100
240	Blockade of oncogenic IB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 11365-70	11.5	127
239	ETO family protein Mtg16 regulates the balance of dendritic cell subsets by repressing Id2. *Journal of Experimental Medicine*, **2014**, 211, 1623-35	16.6	41
238	Diffuse large B-cell lymphoma-treatment approaches in the molecular era. *Nature Reviews Clinical Oncology*, **2014**, 11, 12-23	19.4	274
237	Ibrutinib treatment of CLL: the cancer fights back. *Cancer Cell*, **2014**, 26, 11-3	24.3	25
236	BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. *Human Pathology*, **2014**, 45, 2144-53	3.7	30
235	Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. *Blood*, **2014**, 123, 1214-7	2.2	404
234	Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. *Blood*, **2014**, 123, 1681-90	2.2	87
233	Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. *Blood*, **2014**, 123, 2915-23	2.2	299
232	Oncogenic mechanisms in Burkitt lymphoma. *Cold Spring Harbor Perspectives in Medicine*, **2014**, 4,	5.4	143
231	Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma. *Leukemia and Lymphoma*, **2014**, 55, 1402-3	1.9	12
230	Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma. *Journal of Experimental Medicine*, **2014**, 211, 2497-505	16.6	105
229	Loss of signalling via G13 in germinal centre B-cell-derived lymphoma. *Nature*, **2014**, 516, 254-8	50.4	192

228	B cell super-enhancers and regulatory clusters recruit AID tumorigenic activity. *Cell*, **2014**, 159, 1524-37	56.2	186
227	High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 2349-54	11.5	270
226	Dendritic cell fate is determined by BCL11A. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, E998-1006	11.5	67
225	Monitoring of Circulating Tumor DNA As Minimal Residual Disease in Diffuse Large B-Cell Lymphoma. *Blood*, **2014**, 124, 139-139	2.2	5
224	Cell-of-Origin Assignment in Diffuse Large B-Cell Lymphoma Determined By Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Has Prognostic Significance Independent of IPI and MYC/BCL2 Immunohistochemistry. *Blood*, **2014**, 124, 1624-1624	2.2	1
223	CD28 Mutations in Peripheral T-Cell Lymphomagenesis and Progression. *Blood*, **2014**, 124, 1681-1681	2.2	3
222	Accurate Diagnosis of Aggressive B Cell Non-Hodgkin Lymphomas Using Gene Expression Profiling of Formalin-Fixed, Paraffin-Embedded Tissues. *Blood*, **2014**, 124, 3016-3016	2.2	1
221	IDH2 R172 Mutations Define a Unique Subgroup of Patients in Angioimmunoblastic T-Cell Lymphoma. *Blood*, **2014**, 124, 3580-3580	2.2	2
220	Genetic and Pharmacologic Notch4 Inhibition Synergizes with FLT3 Tyrosine Kinase Inhibition in Vitro to More Effectively Eliminate FLT3/ITD-Positive Leukemia Cells. *Blood*, **2014**, 124, 3583-3583	2.2	2
219	Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma. *Blood*, **2014**, 124, 395-395	2.2	37
218	A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Relapsed/Refractory DLBCL. *Blood*, **2014**, 124, 628-628	2.2	11
217	A Gain-of-Function CCR4 Mutations in Adult T-Cell Leukemia/Lymphoma (ATLL) Enhance the Chemotactic Abilities and PI3K/AKT Activation. *Blood*, **2014**, 124, 3566-3566	2.2	
216	Cell-of-Origin Subtype Classification of Diffuse Large B-Cell Lymphoma Using the Lymph2Cx Assay Retains Relevance in the Context of BCL2 and MYC Expression Status. *Blood*, **2014**, 124, 1667-1667	2.2	
215	Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. *Journal of Clinical Oncology*, **2013**, 31, 4520-8	2.2	93
214	II. Therapy of DLBCL based on genomics. *Hematological Oncology*, **2013**, 31 Suppl 1, 26-8	1.3	13
213	JAKs and STATs in immunity, immunodeficiency, and cancer. *New England Journal of Medicine*, **2013**, 368, 161-70	59.2	545
212	Identification of early replicating fragile sites that contribute to genome instability. *Cell*, **2013**, 152, 620-32	56.2	280
211	Targeting pathological B cell receptor signalling in lymphoid malignancies. *Nature Reviews Drug Discovery*, **2013**, 12, 229-43	64.1	286

210	Control of autophagic cell death by caspase-10 in multiple myeloma. *Cancer Cell*, **2013**, 23, 435-49	24.3	166
209	Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. *New England Journal of Medicine*, **2013**, 368, 1408-16	59.2	388
208	Genome-wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features. *International Journal of Cancer*, **2013**, 133, 2852-63	7.5	11
207	TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. *Cancer Discovery*, **2013**, 3, 564-77	24.4	103
206	Related F-box proteins control cell death in Caenorhabditis elegans and human lymphoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 3943-8	11.5	44
205	Transcription factor Runx2 controls the development and migration of plasmacytoid dendritic cells. *Journal of Experimental Medicine*, **2013**, 210, 2151-9	16.6	76
204	Toll-like receptor signaling. *Cold Spring Harbor Perspectives in Biology*, **2013**, 5, a011247	10.2	173
203	Low-intensity therapy in adults with Burkitt's lymphoma. *New England Journal of Medicine*, **2013**, 369, 1915-25	59.2	248
202	DNA Sequencing-Based Monitoring Of Serum Predicts Clinical Relapse Before CT Imaging in Diffuse Large B-Cell Lymphoma. *Blood*, **2013**, 122, 1767-1767	2.2	2
201	Concurrent Expression Of MYC/BCL2 Protein In Newly Diagnosed DLBCL Is Not Associated With An Inferior Survival Following EPOCH-R Therapy. *Blood*, **2013**, 122, 3029-3029	2.2	7
200	Frequent Activating Mutations Of JAK-STAT Pathway Genes In Natural Killer Cell Lymphomas. *Blood*, **2013**, 122, 812-812	2.2	1
199	Determining Cell-Of-Origin Subtypes In Diffuse Large B-Cell Lymphoma Using Gene Expression Profiling On Formalin-Fixed Paraffin-Embedded Tissue □An L.L.M.P.P. Project. *Blood*, **2013**, 122, 73-73	2.2	
198	Multiplexing high-content flow (HCF) and quantitative high-throughput screening (qHTS) to identify compounds capable of decreasing cell viability, activating caspase 3/7, expressing annexin V, and changing mitochondrial membrane integrity. *Current Protocols in Chemical Biology*, **2013**, 5, 195-212	1.8	6
197	Pathogenetic importance and therapeutic implications of NF-B in lymphoid malignancies. *Immunological Reviews*, **2012**, 246, 359-78	11.3	116
196	Identification of FoxM1/Bub1b signaling pathway as a required component for growth and survival of rhabdomyosarcoma. *Cancer Research*, **2012**, 72, 5889-99	10.1	39
195	Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. *Cancer Cell*, **2012**, 22, 209-21	24.3	202
194	A new "brew" of MALT1 inhibitors. *Cancer Cell*, **2012**, 22, 706-7	24.3	18
193	Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. *Blood*, **2012**, 119, 3757-66	2.2	56

192	Janus kinase deregulation in leukemia and lymphoma. *Immunity*, **2012**, 36, 529-41	32.3	99
191	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. *Nature*, **2012**, 490, 116-20	50.4	600
190	Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. *Blood*, **2012**, 119, 4939-48	2.2	79
189	Pathogenesis of human B cell lymphomas. *Annual Review of Immunology*, **2012**, 30, 565-610	34.7	307
188	Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. *Cancer Cell*, **2012**, 21, 723-37	24.3	386
187	Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. *Journal of Clinical Oncology*, **2012**, 30, 3452-9	2.2	669
186	Congenital B cell lymphocytosis explained by novel germline CARD11 mutations. *Journal of Experimental Medicine*, **2012**, 209, 2247-61	16.6	131
185	Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. *Nature Medicine*, **2012**, 18, 1118-22	50.5	136
184	IRAK4 Kinase As A Novel Therapeutic Target in the ABC Subtype of Diffuse Large B Cell Lymphoma. *Blood*, **2012**, 120, 62-62	2.2	9
183	Gene Expression Signatures That Delineate Biologic and Prognostic Subgroups in Peripheral T-Cell Lymphoma. *Blood*, **2012**, 120, 679-679	2.2	2
182	The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study. *Blood*, **2012**, 120, 686-686	2.2	84
181	TYK2-STAT1 Pathway Positively Regulates BCL2 Gene Expression in T-Cell Acute Lymphoblastic Leukemia. *Blood*, **2012**, 120, 1470-1470	2.2	
180	High Incidence of EZH2 Mutations with Variable Mutation Load in Follicular Lymphoma and Its Consequences for EZH2 Targeted Therapy. *Blood*, **2012**, 120, 545-545	2.2	
179	Genetic Abnormalities in Follicular Lymphoma and Transformed Follicular Lymphoma.. *Blood*, **2012**, 120, 2648-2648	2.2	
178	Malignant pirates of the immune system. *Nature Immunology*, **2011**, 12, 933-40	19.1	104
177	A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. *Blood*, **2011**, 117, 2396-404	2.2	56
176	Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. *Blood*, **2011**, 117, 542-52	2.2	81
175	The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. *Blood*, **2011**, 117, 211-20	2.2	257

174	MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype. *Blood*, **2011**, 118, 5550-8	2.2	63
173	Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. *Haematologica*, **2011**, 96, 558-66	6.6	99
172	High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. *Haematologica*, **2011**, 96, 996-1001	6.6	75
171	Oncogenically active MYD88 mutations in human lymphoma. *Nature*, **2011**, 470, 115-9	50.4	1068
170	MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. *Nature*, **2011**, 471, 377-81	50.4	467
169	The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. *American Journal of Clinical Pathology*, **2011**, 135, 54-61	1.9	60
168	Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues. *Clinical Cancer Research*, **2011**, 17, 3727-32	12.9	60
167	BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. *Clinical Cancer Research*, **2011**, 17, 7785-95	12.9	132
166	The Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 Modulates Chronic Active BCR Signaling and Induces Tumor Regression in Relapsed/Refractory ABC DLBCL. *Blood*, **2011**, 118, 2716-2716	2.2	10
165	Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era. *International Journal of Molecular Epidemiology and Genetics*, **2011**, 2, 245-52	0.9	7
164	Recurrent Oncogenic Mutations in CCND3 in Aggressive Lymphomas. *Blood*, **2011**, 118, 435-435	2.2	
163	Combined Targeting of the MET and FGF Receptor Tyrosine Kinases Induces Sustained AML Cell Death by Preventing Compensatory Upregulation of HGF in Response to MET Kinase Inhibition. *Blood*, **2011**, 118, 1405-1405	2.2	1
162	Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. *Nature*, **2010**, 463, 88-92	50.4	1149
161	Oncogenic activation of NF-kappaB. *Cold Spring Harbor Perspectives in Biology*, **2010**, 2, a000109	10.2	376
160	Aggressive lymphomas. *New England Journal of Medicine*, **2010**, 362, 1417-29	59.2	452
159	Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. *New England Journal of Medicine*, **2010**, 362, 875-85	59.2	961
158	Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. *Blood*, **2010**, 116, 953-61	2.2	105
157	MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. *Blood*, **2010**, 116, 1515-23	2.2	251

156	Cooperative epigenetic modulation by cancer amplicon genes. *Cancer Cell*, **2010**, 18, 590-605	24.3	230
155	Pathway Dependence on the Tyrosine Kinase TYK2 and Its Mediator STAT1 In T-Cell Acute Lymphoblastic Leukemia. *Blood*, **2010**, 116, 3155-3155	2.2	
154	Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP. *Blood*, **2010**, 116, 2005-2005	2.2	
153	Methylation Profiling of Mediastinal Gray Zone Lymphoma Reveals a Distinctive Signature with Elements Shared by Classical Hodgkin's Lymphoma and Mediastinal Large B-Cell Lymphoma. *Blood*, **2010**, 116, 747-747	2.2	
152	Aberrant Expression of Hepatocyte Growth Factor Induces Autocrine MET Activation Providing a Novel Therapeutic Target In Acute Myeloid Leukemia.. *Blood*, **2010**, 116, 1042-1042	2.2	
151	Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 19946-51	11.5	156
150	IRF4: Immunity. Malignancy! Therapy?. *Clinical Cancer Research*, **2009**, 15, 2954-61	12.9	130
149	SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. *Haematologica*, **2009**, 94, 1555-62	6.6	299
148	Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actin. *Journal of Cell Science*, **2009**, 122, 3137-44	5.3	46
147	c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells. *Journal of Virology*, **2009**, 83, 5014-27	6.6	46
146	Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival. *Nature*, **2009**, 458, 92-6	50.4	109
145	Inhibitors of the NF-kappaB activation pathway from Cryptocarya rugulosa. *Journal of Natural Products*, **2009**, 72, 336-9	4.9	55
144	Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. *Blood*, **2009**, 114, 826-34	2.2	136
143	Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV. *Leukemia and Lymphoma*, **2009**, 50, 1875-8	1.9	9
142	A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. *Clinical Cancer Research*, **2009**, 15, 5494-502	12.9	507
141	Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. *Blood*, **2009**, 113, 6069-76	2.2	422
140	Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. *Blood*, **2009**, 113, 2298-301	2.2	69
139	CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression. *Haematologica*, **2009**, 94, 596-8	6.6	18

138	Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. *Journal of Clinical Investigation*, **2009**, 119, 3395-407	15.9	207
137	Comparative Clinical and Biological Features of Primary Mediastinal B-Cell Lymphoma (PMBL) and Mediastinal Grey Zone Lymphoma (MGZL).. *Blood*, **2009**, 114, 106-106	2.2	9
136	OCT2 (Octamer Binding Protein 2): An Essential Role in Germinal Center B Cell Differentiation and the Achilles Heel of Derived Lymphomas.. *Blood*, **2009**, 114, 362-362	2.2	1
135	The MMSET Histone Methyl Transferase Alters Chromatin Structure and Gene Expression in t(4;14) Multiple Myeloma Cells.. *Blood*, **2009**, 114, 675-675	2.2	
134	Accurate Classification of Diffuse Large B Cell Lymphoma Into Germinal Center and Activated B Cell Subtypes Using a Nuclease Protection Assay On Formalin Fixed Paraffin Embedded Tissue: A Study From the Lymphoma and Leukemia Molecular Profiling Project.. *Blood*, **2009**, 114, 620-620	2.2	
133	Bortezomib Resistance in Mantle Cell Lymphoma Is Associated with Expression of a Plasmacytoid Differentiation Program.. *Blood*, **2009**, 114, 287-287	2.2	1
132	MYC Translocations and Expression Are Clinically Important in R-CHOP Treated Patients with De Novo DLBCL.. *Blood*, **2009**, 114, 1100-1100	2.2	
131	Chromosomal Alterations in Gene Expression-Defined Pediatric Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL).. *Blood*, **2009**, 114, 2922-2922	2.2	
130	High Microvascular Density Correlates with Poor Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab Plus Chemotherapy (R-CT).. *Blood*, **2009**, 114, 1948-1948	2.2	
129	IRF4 addiction in multiple myeloma. *Nature*, **2008**, 454, 226-31	50.4	477
128	Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. *Science*, **2008**, 319, 1676-9	33.3	660
127	Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 13520-5	11.5	746
126	Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. *Clinical Cancer Research*, **2008**, 14, 396-404	12.9	173
125	Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma. *Haematologica*, **2008**, 93, 1327-34	6.6	72
124	Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 20798-803	11.5	72
123	Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. *Blood*, **2008**, 111, 3701-13	2.2	287
122	Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput screens of NFkappaB activation. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 329-35	2.9	16
121	Loss of CIITA and MHC Class II Expression in Diffuse Large B-Cell Lymphoma Is Not Explained by Methylation of CIITA Promoters III and IV.. *Blood*, **2008**, 112, 1786-1786	2.2	

120	Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma. *Blood*, **2008**, 112, 475-475	2.2	
119	Genetic Abnormalities Involved in the Development and Progression of Follicular Lymphoma.. *Blood*, **2008**, 112, 2049-2049	2.2	
118	The Mir-17~92 Cluster Enhances Cell Growth and Resistance to Chemotherapy in Mantle Cell Lymphoma by Down-Regulating PTEN, PHLPP2 and BIM. *Blood*, **2008**, 112, 373-373	2.2	1
117	Genome-Wide Expression Profiling Predicts Treatment Outcome in Classical Hodgkin Lymphoma. *Blood*, **2008**, 112, 520-520	2.2	
116	A closer look at follicular lymphoma. *New England Journal of Medicine*, **2007**, 356, 741-2	59.2	53
115	C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma. *International Journal of Cancer*, **2007**, 120, 1387-95	7.5	66
114	Frequent occurrence of deletions in primary mediastinal B-cell lymphoma. *Genes Chromosomes and Cancer*, **2007**, 46, 1090-7	5	32
113	Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. *British Journal of Haematology*, **2007**, 136, 286-93	4.5	124
112	Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. *Cancer Cell*, **2007**, 12, 115-30	24.3	789
111	Repression of BCL-6 is required for the formation of human memory B cells in vitro. *Journal of Experimental Medicine*, **2007**, 204, 819-30	16.6	68
110	The BCL-2 biomarker in the era of molecular diagnosis of diffuse large B-cell lymphoma. *Leukemia and Lymphoma*, **2007**, 48, 1061-3	1.9	3
109	Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. *Journal of Experimental Medicine*, **2007**, 204, 633-43	16.6	160
108	Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. *Journal of Clinical Oncology*, **2007**, 25, 3321-9	2.2	97
107	Characterization of early stages of human B cell development by gene expression profiling. *Journal of Immunology*, **2007**, 179, 3662-71	5.3	117
106	BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?. *Blood*, **2007**, 109, 843-4; discussion 844-5	2.2	10
105	Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. *Blood*, **2007**, 109, 4599-606	2.2	183
104	Ribosomal protein S3: a KH domain subunit in NF-kappaB complexes that mediates selective gene regulation. *Cell*, **2007**, 131, 927-39	56.2	254
103	Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. *Blood*, **2007**, 109, 271-80	2.2	211

102	A cell-based assay for IkappaBalpha stabilization using a two-color dual luciferase-based sensor. *Assay and Drug Development Technologies*, **2007**, 5, 85-103	2.1	30
101	Gene Expression Signatures Predict Overall Survial in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy.. *Blood*, **2007**, 110, 348-348	2.2	6
100	CARD11 as an Oncogene in Diffuse Large B Cell Lymphoma.. *Blood*, **2007**, 110, 692-692	2.2	2
99	Distinct Genetic Aberrations in Molecular Subtypes of Diffuse Large B Cell Lymphoma Detected by Array CGH.. *Blood*, **2007**, 110, 2631-2631	2.2	
98	Follicular Lymphomas with and without Translocation t(14;18) Differ in Gene Expression Profiles and Genetic Alterations.. *Blood*, **2007**, 110, 360-360	2.2	1
97	Transformation of late passage insulin-like growth factor-I receptor null mouse embryo fibroblasts by SV40 T antigen. *Cancer Research*, **2006**, 66, 4233-9	10.1	5
96	BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. *Journal of Clinical Oncology*, **2006**, 24, 961-8	2.2	238
95	Molecular diagnosis of Burkitt's lymphoma. *New England Journal of Medicine*, **2006**, 354, 2431-42	59.2	700
94	Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 2352-7	11.5	116
93	Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. *Immunity*, **2006**, 25, 225-36	32.3	400
92	A library of gene expression signatures to illuminate normal and pathological lymphoid biology. *Immunological Reviews*, **2006**, 210, 67-85	11.3	165
91	Genomics & proteomics: reduce, rebuild, reveal. *Immunological Reviews*, **2006**, 210, 5-7	11.3	1
90	A loss-of-function RNA interference screen for molecular targets in cancer. *Nature*, **2006**, 441, 106-10	50.4	496
89	Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. *Blood*, **2006**, 107, 1101-7	2.2	60
88	DA-EPOCH-R Is Highly Effective in Both BCL-6+ and BCL-6− Untreated De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Study Update and Analysis of Survival Outcomes for Multiple Biomarkers.. *Blood*, **2006**, 108, 206-206	2.2	3
87	Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome May Be Significantly Improved by the Addition of Rituximab to Dose-Adjusted (DA)-EPOCH and Obviates the Need for Radiation: Results from a Prospective Study of 44 Patients.. *Blood*, **2006**, 108, 209-209	2.2	5
86	Aberrant Immunoglobulin Class Switch Recombination and Switch Translocations in Activated B Cell-Like Diffuse Large B-Cell Lymphoma.. *Blood*, **2006**, 108, 356-356	2.2	1
85	Gene Expression Differences between Low and High Stage Diffuse Large B Cell Lymphoma (DLBCL).. *Blood*, **2006**, 108, 809-809	2.2	9

84	Characterization of Early Human B Cell Development by Gene Expression Profiling.. *Blood*, **2006**, 108, 1352-1352	2.2	
83	Structural Profiles of p53 Gene Mutations Predict Clinical Outcome in Diffuse Large B-Cell Lymphoma: An International Collaborative Study.. *Blood*, **2006**, 108, 811-811	2.2	
82	Molecular Diagnosis of the Lymphomas by Gene Expression Profiling **2006**, 110-126		1
81	Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. *Blood*, **2005**, 106, 3183-90	2.2	304
80	The biology of human lymphoid malignancies revealed by gene expression profiling. *Advances in Immunology*, **2005**, 87, 163-208	5.6	174
79	MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells. *Blood*, **2005**, 105, 2891-9	2.2	65
78	Insertion of Myc into Igh accelerates peritoneal plasmacytomas in mice. *Cancer Research*, **2005**, 65, 7644-52	12.1	22
77	Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome Is Significantly Improved by the Addition of Rituximab to Dose Adjusted (DA)-EPOCH and Overcomes the Need for Radiation.. *Blood*, **2005**, 106, 929-929	2.2	11
76	Biological Differences in Peripheral T-Cell Lymphomas Identified by DNA Microarrays.. *Blood*, **2005**, 106, 3012-3012	2.2	
75	Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. *Clinical Cancer Research*, **2005**, 11, 28-40	12.9	220
74	Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. *Journal of Virology*, **2004**, 78, 4108-19	6.6	194
73	Active NF-kappaB signalling is a prerequisite for influenza virus infection. *Journal of General Virology*, **2004**, 85, 2347-2356	4.9	174
72	Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. *Journal of Immunology*, **2004**, 173, 1158-65	5.3	287
71	Cancer: negative feedback for B cells. *Nature*, **2004**, 431, 919-20	50.4	8
70	Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. *Cancer Cell*, **2004**, 5, 191-9	24.3	284
69	Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. *Blood*, **2004**, 103, 275-82	2.2	2955
68	Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. *Human Molecular Genetics*, **2004**, 13, 1827-37	5.6	109
67	Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. *New England Journal of Medicine*, **2004**, 351, 2159-69	59.2	1141

66	BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. *American Journal of Pathology*, **2004**, 165, 159-66	5.8	232
65	XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. *Immunity*, **2004**, 21, 81-93	32.3	739
64	Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. *Blood*, **2004**, 104, 3647-54	2.2	612
63	ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. *Lancet, The*, **2004**, 363, 105-11	40	465
62	Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. *Blood*, **2004**, 103, 4251-8	2.2	256
61	Phase I/II study of Bortezomib Alone and Bortezomib with Dose-Adjusted EPOCH Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma.. *Blood*, **2004**, 104, 1385-1385	2.2	8
60	Dose-Adjusted EPOCH-Rituximab Is Highly Effective in the GCB and ABC Subtypes of Untreated Diffuse Large B-Cell Lymphoma.. *Blood*, **2004**, 104, 159-159	2.2	4
59	Tissue Microarray Is a Useful Tool in the Evaluation of Genes Implicated in Transformation of Follicular Lymphoma.. *Blood*, **2004**, 104, 2267-2267	2.2	1
58	High Cyclin D1 Expression Is Associated with Increased Proliferation Rate and Decreased Survival in Mantle Cell Lymphoma (MCL) and Is Caused by Genomic Deletions and Mutations that Enhance Stability of Cyclin D1 mRNA.. *Blood*, **2004**, 104, 697-697	2.2	
57	Chromosomal Imbalances in Germinal Center B-Cell-Like and Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Influence Gene Expression Signatures and Improve Gene Expression-Based Survival Prediction(the First Two Authors Contributed Equally to This Work).. *Blood*, **2004**, 104, 415-415	2.2	
56	The Natural History of Mutated, Stage AO Chronic Lymphocytic Leukemia.. *Blood*, **2004**, 104, 954-954	2.2	
55	A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 9991-6	11.5	768
54	ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. *Blood*, **2003**, 101, 4944-51	2.2	650
53	Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. *Blood*, **2003**, 101, 4576-82	2.2	89
52	The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. *Cancer Cell*, **2003**, 3, 185-97	24.3	751
51	Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. *Journal of Experimental Medicine*, **2003**, 198, 851-62	16.6	869
50	Two newly characterized germinal center B-cell-associated genes, GCET1 and GCET2, have differential expression in normal and neoplastic B cells. *American Journal of Pathology*, **2003**, 163, 135-44	5.8	33
49	Towards molecular diagnosis and targeted therapy of lymphoid malignancies. *Seminars in Hematology*, **2003**, 40, 296-307	4	21

48	Molecular diagnosis of the hematologic cancers. *New England Journal of Medicine*, **2003**, 348, 1777-85	59.2	162
47	MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. *Blood*, **2003**, 101, 4539-46	2.2	167
46	Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression. *Molecular and Cellular Biology*, **2003**, 23, 9375-88	4.8	109
45	Analysis of gamma c-family cytokine target genes. Identification of dual-specificity phosphatase 5 (DUSP5) as a regulator of mitogen-activated protein kinase activity in interleukin-2 signaling. *Journal of Biological Chemistry*, **2003**, 278, 5205-13	5.4	78
44	Linking laboratory and clinical research: the development of molecularly targeted therapeutics inside the national cancer institute center for cancer research. *Clinical Advances in Hematology and Oncology*, **2003**, 1, 302-6	0.6	2
43	Clinical translation of gene expression profiling in lymphomas and leukemias. *Seminars in Oncology*, **2002**, 29, 258-63	5.5	39
42	Focus on lymphomas. *Cancer Cell*, **2002**, 2, 363-6	24.3	18
41	The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-kappaB signal transduction pathway. *Oncogene*, **2002**, 21, 8759-68	9.2	47
40	Lymphoid malignancies: the dark side of B-cell differentiation. *Nature Reviews Immunology*, **2002**, 2, 920-32	32.5	310
39	Stereotyped and specific gene expression programs in human innate immune responses to bacteria. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 972-7	11.5	337
38	Molecular diagnosis of lymphoid malignancies by gene expression profiling. *Current Opinion in Hematology*, **2002**, 9, 333-8	3.3	51
37	The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. *Blood*, **2002**, 99, 2285-90	2.2	246
36	Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. *Blood*, **2002**, 99, 2685-93	2.2	249
35	Gene expression profiling of lymphoid malignancies. *Annual Review of Medicine*, **2002**, 53, 303-18	17.4	101
34	The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. *New England Journal of Medicine*, **2002**, 346, 1937-47	59.2	2971
33	Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. *Immunity*, **2002**, 17, 51-62	32.3	789
32	It's ALL in the diagnosis. *Cancer Cell*, **2002**, 1, 109-10	24.3	22
31	Gene regulation mediated by calcium signals in T lymphocytes. *Nature Immunology*, **2001**, 2, 316-24	19.1	469

30	Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. *Journal of Experimental Medicine*, **2001**, 194, 1861-74	16.6	871
29	Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. *Journal of Experimental Medicine*, **2001**, 194, 1639-47	16.6	882
28	Molecular definition of the germinal centre stage of B-cell differentiation. *Philosophical Transactions of the Royal Society B: Biological Sciences*, **2001**, 356, 83-9	5.8	9
27	Gene expression physiology and pathophysiology of the immune system. *Trends in Immunology*, **2001**, 22, 35-40	14.4	54
26	Signatures of the immune response. *Immunity*, **2001**, 15, 375-85	32.3	279
25	Molecular features of B-cell lymphoma. *Current Opinion in Oncology*, **2001**, 13, 316-24	4.2	42
24	Genomic-scale gene expression profiling of normal and malignant immune cells. *Current Opinion in Immunology*, **2000**, 12, 219-25	7.8	99
23	Circulating human B cells that express surrogate light chains and edited receptors. *Nature Immunology*, **2000**, 1, 207-13	19.1	100
22	Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature*, **2000**, 403, 503-11	50.4	7592
21	The molecular and cellular origins of Hodgkin's disease. *Journal of Experimental Medicine*, **2000**, 191, 207-12	16.6	90
20	Genomic views of the immune system*. *Annual Review of Immunology*, **2000**, 18, 829-59	34.7	152
19	BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. *Immunity*, **2000**, 13, 199-212	32.3	697
18	Regulation of lymphocyte cell fate decisions and lymphomagenesis by BCL-6. *International Reviews of Immunology*, **1999**, 18, 381-403	4.6	64
17	Analysis of gene expression in lymphoid malignancies using the Lymphochip cDNA microarray. *Nature Genetics*, **1999**, 23, 22-22	36.3	1
16	The transcriptional program in the response of human fibroblasts to serum. *Science*, **1999**, 283, 83-7	33.3	1713
15	Reed-Sternberg Cell Genome Expression Supports a B-Cell Lineage. *Blood*, **1999**, 94, 411-416	2.2	4
14	Probing lymphocyte biology by genomic-scale gene expression analysis. *Journal of Clinical Immunology*, **1998**, 18, 373-9	5.7	82
13	Control of inflammation, cytokine expression, and germinal center formation by BCL-6. *Science*, **1997**, 276, 589-92	33.3	763

12	Immune responses in mice deficient in Ly-GDI, a lymphoid-specific regulator of Rho GTPases. *Molecular Immunology*, **1997**, 34, 481-91	4.3	41
11	Transcriptional activation by Oct-3: evidence for a specific role of the POU-specific domain in mediating functional interaction with Oct-1. *Nucleic Acids Research*, **1996**, 24, 2112-8	20.1	34
10	Carboxyl-terminal targeting and novel post-translational processing of JAW1, a lymphoid protein of the endoplasmic reticulum. *Journal of Biological Chemistry*, **1996**, 271, 23528-34	5.4	26
9	Retraction: Oct-3 is a maternal factor required for the first mouse embryonic division. *Cell*, **1992**, 69, 724	56.2	2
8	A B cell population that dominates the primary response to influenza virus hemagglutinin does not participate in the memory response. *European Journal of Immunology*, **1991**, 21, 2687-95	6.1	46
7	Chromosomal location of the octamer transcription factors, Otf-1, Otf-2, and Otf-3, defines multiple Otf-3-related sequences dispersed in the mouse genome. *Genomics*, **1991**, 10, 313-26	4.3	56
6	Oct-3 is a maternal factor required for the first mouse embryonic division. *Cell*, **1991**, 64, 1103-10	56.2	55
5	A POU-domain transcription factor in early stem cells and germ cells of the mammalian embryo. *Nature*, **1990**, 345, 686-92	50.4	809
4	A human protein specific for the immunoglobulin octamer DNA motif contains a functional homeobox domain. *Cell*, **1988**, 55, 135-44	56.2	239
3	An octamer oligonucleotide upstream of a TATA motif is sufficient for lymphoid-specific promoter activity. *Nature*, **1987**, 329, 174-8	50.4	405
2	A lymphoid-specific protein binding to the octamer motif of immunoglobulin genes. *Nature*, **1986**, 323, 640-3	50.4	728
1	Genome-wide Screens Identify Lineage- and Tumor Specific-Genes Modulating MHC-I and MHC-II Immunosurveillance in Human Lymphomas		1